Some reports claim that gentamicin and amikacin levels may be raised by indometacin, and that amikacin levels may be raised by ibuprofen
lysine, when given to premature babies to treat patent ductus arteriosus, whereas others have not found an interaction.
Concurrent use should be closely monitored because of the toxicity
that is associated with raised aminoglycoside levels. It has been suggested that the aminoglycoside dosage should be reduced before giving indometacin. It has also been suggested that the dose interval of amikacin should be increased by at least 6 to 8 hours if ibuprofen
lysine is also given during the first days of life. The serum
levels of the aminoglycosides
function should be well monitored during concurrent use. Other aminoglycosides
possibly behave similarly. This interaction does not seem to have been studied in adults.